Skip to content

Gottlieb AB (2001) Psoriasis: immunopathology and immuno-modulation

1: Berger EM, Gottlieb AB. Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol. 18: Gottlieb AB. Psoriasis. Immunopathology and immunomodulation. Dermatol Clin. 2001 Oct;19(4):649-57, viii. Review. 19: Gottlieb AB. Psoriasis. Immunopathology and immunomodulation. Dermatol Clin. 2001 Oct;19(4):649-57, viii. Psoriasis: Immunopathology and immunomodulation on ResearchGate, the professional network for scientists.

Gottlieb AB (2001) Psoriasis: immunopathology and immuno-modulation 2Psoriasis. Immunopathology and immunomodulation. Dermatol Clin. Dermatol Clin 2001 Oct;19(4):649-57, viii. A B Gottlieb. Biologics in development for the treatment of moderate to severe plaque-type psoriasis are discussed in this article. Psoriasis, a chronic autoimmune disease of the skin and/or joints, affects a patient’s appearance, selfesteem, and quality of life. 1.Gottlieb, A.B. Psoriasis: immunopathology and immunomodulation. Dermatol Clin. 2001;19:649657. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.

8Weinstein, G.D., Menter, M.A. An overview of psoriasis. in: G.D. Weinstein, A.B. Gottlieb (Eds.) Therapy of moderate to severe psoriasis. 2nd ed. 2001;137:14471454. 13Gottlieb, A.B. Psoriasis: immunopathology and immunomodulation. National Psoriasis Foundation benchmark survey on psoriasis and psoriatic arthritis summary of top-line results, 2002. 29Chaudhari, U., Romano, P., Mulcahy, L.D., Dooley, L.T., Baker, D.G., Gottlieb, A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Et al, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862. Immunopathology and immunomodulation. Immunopathology and immunomodulatio was found in Unbound MEDLINE. Download PubMed App to iPhone, iPad, Android smartphone and tablet. Psoriasis. Immunopathology and immunomodulation.

Psoriasis. Immunopathology And Immunomodulation

2165 results. Tharp MD, Longley BJ; Mastocytosis. Journal Article, Review; Dermatol Clin 2001 Oct; 19(4):679-96, viii-ix. Gottlieb AB; Psoriasis. Immunopathology and immunomodulation. Journal Article, Review; Dermatol Clin 2001 Oct; 8Gottlieb, A.B. Psoriasis. Immunopathology and immunomodulation. C.E.M. et al, Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment. Gottlieb, A. B. Immunopathology and immunomodulation. Med. Dermatol. 19, 649657 (2001). It should be realized that biologic therapies for psoriasis are very new and that efficacy and safety information from clinical trials is just becoming available. Gottlieb AB. Psoriasis-Immunopathology and immunomodulation. Dermatol Clin 2001;19:649-57. Back to cited text no. 19. Reserve systemic therapy for patients with moderate to severe psoriasis. Until more long-term safety data become available, be cautious about prescribing biologic agents for patients at risk for infection (particularly tuberculosis) and malignancy. Gottlieb AB. Psoriasis. Immunopathology and immunomodulation. Dermatol Clin. 2001;19:649-657, viii. 6. Walsh SR, Shear NH.

References In Clinics In Dermatology

9Gottlieb AB. Psoriasis: immunopathology and immunomodulation. Dermatol Clin North Am (in press). Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, McInnes IB. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. Immunopathology and immunomodulation. 2001 Oct; 19(4):649-57, viii.